• Odyssey Therapeutics flagged additional Phase 2a induction results for OD-001 in moderate to severe ulcerative colitis.
• Data will be presented in a future oral session at UEG Week 2026 in Barcelona on Oct. 20.
• Presentation is set to cover the study’s safety profile and signs of clinical benefit, without new technical detail disclosed in the announcement.
• A conference call and webcast on Oct. 20 will discuss additional induction data beyond what is shown at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840226) on October 06, 2026, and is solely responsible for the information contained therein.